Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) (ITUB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)Trade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) vs Regeneron Pharmaceuticals Inc — how do they compare? Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) trades at $9.95 (market cap $112.95B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.14B). The key difference: Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) is the larger of the two by market cap, and Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) pays the higher dividend (1.74%). Which is the better fit depends on your goals — on Pluang, investors hold Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares) for 0 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.

ITUBREGN
Market Cap
$112.95B$76.14B
Volume
44,012,203500,239
Sector
FinancialsHealth
52-Week High
$10.15$852.03
52-Week Low
$6.76$557.73
Typical Hold Time
0 Days107 Days
Enterprise Value
$1.33T$70.85B
Dividend Yield
1.74%0.51%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.

The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ITUB
100% Buy0% Sell
Avg holding period · 0 Days
REGN
98% Buy2% Sell
Avg holding period · 107 Days

About Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

Itaú Unibanco is a Brazilian financial services company providing banking, credit, insurance, and investment products. It serves individual, business, and corporate clients.

Read more on ITUB →

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN →